Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC
10:10am, Monday, 25'th Nov 2024
If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.
3 Dividend Stocks That Are Screaming Buys in November
07:20am, Saturday, 23'rd Nov 2024
Political uncertainty has created buying opportunities among blue-chip healthcare stocks with big-time dividends.
2 Unstoppable Dividend Stocks to Buy Now With $500
05:36am, Saturday, 23'rd Nov 2024
2 Unstoppable Dividend Stocks to Buy Now With $500
2 Dow Jones Dividend Stocks With Yields Above 3% You Can Buy Now and Hold at Least a Decade
04:02am, Saturday, 23'rd Nov 2024
2 Dow Jones Dividend Stocks With Yields Above 3% You Can Buy Now and Hold at Least a Decade
Following recent U.S. FDA approval of TREMFYA® for adults with moderately to severely active ulcerative colitis (UC), this submission underscores its potential to be the only IL-23 inhibitor that off
3 Dividend Kings So You Can Sleep Well At Night
07:15am, Friday, 22'nd Nov 2024
Dividend Kings, like Coca-Cola, Johnson & Johnson, and Walmart, are prime long-term investments due to their consistent dividend growth over 50+ years. Coca-Cola offers a 3% yield and strong EBITDA gr
Which Is A Better Pick: JNJ Stock Or AbbVie?
08:00am, Thursday, 21'st Nov 2024
Given its better prospects, we believe that AbbVie stock (NYSE: ABBV) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). Both AbbVie and J&J trade at 15x forward expec
Of 63 Fortune 500 Industry Leaders, 57 Pay Dividends, 38 Are Cash Rich And 1 Is A Buy
04:05pm, Wednesday, 20'th Nov 2024
AT&T, Altria Group, and Energy Transfer are top buys with dividends from $1K invested exceeding single share prices, meeting the dogcatcher ideal. Analysts forecast 15.47% to 28.33% net gains by Novem
J&J Loses Around $24B in a Month: How to Play the Stock?
04:00pm, Wednesday, 20'th Nov 2024
The decline in J&J's share price and the drug/biotech sector's downturn in the past month have left investors wondering if they should sell J&J stock.
If I Could Only Buy 2 High Dividend Yield Companies In November 2024: Both Yield Above 6%
06:00pm, Tuesday, 19'th Nov 2024
I have selected Pfizer and Verizon as my top two high dividend yield companies to invest in for November 2024. Both pay an attractive Dividend Yield [FWD] of 6.14% (Pfizer) and 6.58% (Verizon) and hav
Johnson & Johnson: Policy Uncertainty Elevated, But Shares Remain Inexpensive
10:50am, Tuesday, 19'th Nov 2024
The Health Care sector faces uncertainty due to speculation about Robert F. Kennedy, Jr. leading HHS, impacting stocks like Johnson & Johnson. Despite solid earnings, JNJ shares have been under pressu
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
10:06am, Tuesday, 19'th Nov 2024
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
More than 90 presentations of clinical trial and real-world data highlight potentially practice-changing evidence and commitment to pioneer the next wave of therapies for patients with hematologic mal
J&J's skin disease drug meets main goals of late-stage study
05:10pm, Monday, 18'th Nov 2024
Johnson & Johnson's drug for a type of skin condition met the main goals in a late-stage trial, the drugmaker said on Monday.
ICONIC-LEAD achieved its co-primary endpoints of PASI-90 and IGA of 0 or 1 at week 16; 74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24 ICONIC-TOTAL achieved its primary endpoi
